• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Camarus, Braeburn tout Phase II data for long-acting buprenorphine depot

June 23, 2017 By Sarah Faulkner

Camurus, Braeburn PharmaceuticalsCamarus AB (STO:CAMX) and Braeburn Pharmaceuticals touted data yesterday from a Phase II trial of its long-acting buprenorphine depot. The 47-patient trial found that CAM2038 blocks the effects of opioids and suppresses withdrawal symptoms in adults with opioid use disorder.

The in-patient trial included 5 3-day test sessions to evaluate the patients’ response to randomized intramuscular hydromorphone injections. After the 1st 3-day session, patients were randomized to weekly CAM2038 at 24mg or 32mg and the assigned dose was given at day 0 and day 7.

Researchers conducted 4 sets of hydromorphone sessions to evaluate the depot’s ability to block the effects of opioids.

“CAM2038 produced clinically relevant buprenorphine plasma levels, translating into rapid and sustained opioid blockade and withdrawal suppression, and was well tolerated both systemically and locally,” trial investigator Sharon Walsh said in prepared remarks. “As reported in JAMA Psychiatry, trial results suggest that CAM2038 formulations would be effective in reducing illicit opioid use and relapse, while eliminating the risk for misuse and diversion.”

The study met the primary endpoint for both dosages, blocking the effects of hydromorphone and suppressing withdrawal. The concentration of buprenorphine in patients’ plasma peaked at 24 hours, with CAM2038 sporting an apparent half-life of 4 to 5 days.

The product was safely tolerated and had adverse events consistent with other trials, including injection-site pain and constipation.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news

Filed Under: Clinical Trials, Featured, Pain Management, Pharmaceuticals Tagged With: Braeburn Pharmaceuticals, Camarus AB

IN CASE YOU MISSED IT

  • Senseonics stock is up on Q2 results
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS